Comparative Pharmacology
Head-to-head clinical analysis: NUVIGIL versus SOLRIAMFETOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUVIGIL versus SOLRIAMFETOL.
NUVIGIL vs SOLRIAMFETOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NUVIGIL (armodafinil) is the R-enantiomer of modafinil. Its precise mechanism is unknown, but it is thought to involve dopamine reuptake inhibition, leading to increased extracellular dopamine levels. It also affects other neurotransmitters such as norepinephrine, serotonin, and histamine.
Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor (DNRI). It increases extracellular levels of dopamine and norepinephrine by blocking their reuptake via the dopamine transporter (DAT) and norepinephrine transporter (NET), respectively, without significant affinity for other monoamine transporters or receptors.
150 mg or 250 mg orally once daily in the morning.
2.5 mg orally once daily, titrated to 5 mg daily after 2 weeks; maximum 7.5 mg daily.
None Documented
None Documented
The terminal elimination half-life of the (R)-enantiomer (armodafinil) is approximately 15 hours, compared to 12-15 hours for racemic modafinil. The half-life is prolonged in patients with hepatic impairment (Child-Pugh Class B or C: ~20-25 hours) and in elderly patients (up to 20 hours). Clinically, this supports once-daily dosing.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30-40 hours) requiring dose adjustment.
Primarily renal excretion of metabolites and unchanged drug. Approximately 80% of a radiolabeled dose is recovered in urine over 7 days, with about 45% as unchanged armodafinil and 20% as the acid metabolite. Fecal excretion accounts for about 1%.
Primarily renal excretion as unchanged drug and metabolites: 70-80% in urine, with about 30% unchanged; biliary/fecal elimination accounts for 15-20%.
Category C
Category C
Wakefulness-Promoting Agent
Wakefulness-Promoting Agent